HOXA9 and acute myeloid leukemia: The moribund mice that received the NUP98-HOXA9 AML cells developed leukemia, as evidenced by splenomegaly, pale tibias, and markedly increased numbers of immature myeloid cells in PB and BM as compared with mice that received HOXBLINC-KD cells or the PBS control (Figure 8E and Supplemental Figure 8D).